Cognitive Bias Modification: Exploring the effects of a computer-based cognitive bias training in patients with acute myeloid leukemia at risk for depression and anxiety symptoms -(HemaCogTrain)

Completed

Conditions: acute myeloid leukaemia
blood cancer
10024324

Registration Number: NL-OMON46134

Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 20

Inclusion Criteria

- Subjected to the ward of the department of hematology-oncology for treatment of a AML
- Hightened level of distress as measured with the *Distress Thermometer*. A *Distress Thermometer* score of 5 or higher was originally recommended as denoting significant distress necessitating psychosocial referral (National Comprehensive Cancer Network, 2005). Patients with a score of 8 or higher in the HADS will be considered for participation in the study. (HADS; Zigmond & Snaith, 1983). This cut-off shows good sensitivity and specificity in a somatic patient population (Bjelland et al., 2002).
- Signed IRB-approved informed consent form

Exclusion Criteria

- Impossibility to obtain a valid informed consent
- Severe depression or other psychiatric disorders that interfere with the ability to receive a cognitive intervention of 20 minutes per day
- Insufficient comprehension of the Dutch language
- IQ estimate < 80 points
- Acuteness of symptoms that prevent patient from attentively doing the task 20 min

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study parameters are change in affective (i.e., depression and anxiety)<br /><br>and distress symptoms as measured by the HADS and the DASS 21. All primary<br /><br>measures are sampled before and directly after as well as 1 week after the<br /><br>intervention. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>earlier life stress, psychological and cognitive aspects, and coping abilities<br /><br>may modulate the vulnerability. Impact of these variables on the primary<br /><br>outcome will be a secondary endpoint as well as individual clinical progression<br /><br>of each individual patient after three- four weeks of treatment.</p><br>